Raw conjoint results used alone rarely reflect eventual market shares. We have discussed in a previous article how to transform conjoint preference shares into market shares using pharma-validated elasticities. In this article, we walk you through five evidence-based steps to transform conjoint market shares into more accurate eventual market shares.